CoChat

Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

UNLABELLED: ABSTRACT Chronic, biofilm-like infections by the opportunistic pathogen Pseudomonas aeruginosa are a major cause of mortality in cystic fibrosis (CF) patients. While much is known about P. aeruginosa from laboratory studies, far less is understood about what it experiences in vivo. Iron is an important environmental parameter thought to play a central role in the development and maintenance of P. aeruginosa infections, for both anabolic and signaling purposes. Previous studies have focused on ferric iron [Fe(III)] as a target for antimicrobial therapies; however, here we show that ferrous iron [Fe(II)] is abundant in the CF lung (-39 µM on average for severely sick patients) and significantly correlates with disease severity (ρ = -0.56, P = 0.004), whereas ferric iron does not (ρ = -0.28, P = 0.179). Expression of the P. aeruginosa genes bqsRS, whose transcription is upregulated in response to Fe(II), was high in the majority of patients tested, suggesting that increased Fe(II) is bioavailable to the infectious bacterial population. Because limiting Fe(III) acquisition inhibits biofilm formation by P. aeruginosa in various oxic in vitro systems, we also tested whether interfering with Fe(II) acquisition would improve biofilm control under anoxic conditions; concurrent sequestration of both iron oxidation states resulted in a 58% reduction in biofilm accumulation and 28% increase in biofilm dissolution, a significant improvement over Fe(III) chelation treatment alone. This study demonstrates that the chemistry of infected host environments coevolves with the microbial community as infections progress, which should be considered in the design of effective treatment strategies at different stages of disease. IMPORTANCE: Iron is an important environmental parameter that helps pathogens thrive in sites of infection, including those of cystic fibrosis (CF) patients. Ferric iron chelation therapy has been proposed as a novel therapeutic strategy for CF lung infections, yet until now, the iron oxidation state has not been measured in the host. In studying mucus from the infected lungs of multiple CF patients from Europe and the United States, we found that ferric and ferrous iron change in concentration and relative proportion as infections progress; over time, ferrous iron comes to dominate the iron pool. This information is relevant to the design of novel CF therapeutics and, more broadly, to developing accurate models of chronic CF infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.00557-13

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Direct detection of iron abundance and oxidation state within CF sputum. Total iron [Fe(III) plus Fe(II)] (A), Fe(II) (B), and Fe(II) % (D) all increase as pulmonary function (FEV1%) declines. There is no significant increase in Fe(III) (C). Each point represents the average of measurements on multiple sputum samples from a single CF patient.
FIG 1 Direct detection of iron abundance and oxidation state within CF sputum. Total iron [Fe(III) plus Fe(II)] (A), Fe(II) (B), and Fe(II) % (D) all increase as pulmonary function (FEV1%) declines. There is no significant increase in Fe(III) (C). Each point represents the average of measurements on multiple sputum samples from a single CF patient.CC BY-NC-SA · PubMed Central
FIG 2 Fe(II) percentage of the total iron pool relative to sputum phenazine content. Fe(II) dominates the iron pool at high concentrations of total phenazines (PYO plus PCA) (A) and phenazine-1-carboxylic acid (PCA) (B) but not pyocyanin (PYO) (C). These data likely reflect the higher reactivity of PCA with Fe(III) under anoxic conditions (30).
FIG 2 Fe(II) percentage of the total iron pool relative to sputum phenazine content. Fe(II) dominates the iron pool at high concentrations of total phenazines (PYO plus PCA) (A) and phenazine-1-carboxylic acid (PCA) (B) but not pyocyanin (PYO) (C). These data likely reflect the higher reactivity of PCA with Fe(III) under anoxic conditions (30).CC BY-NC-SA · PubMed Central
FIG 3 (A) Fe(II)-relevant gene expression in CF sputum. bqsS is upregulated in planktonic cultures of P. aeruginosa in response to 50 µM Fe(II) (black) relative to 50 µM Fe(III) (white) or no treatment (light gray). A similar result is seen with bqsR. Points represent average CT values from three independent experiments; bars represent the standard deviations. By comparison, expression levels of these Fe(II)-sensitive genes in CF sputum (dark gray) vary over 5 orders of magnitude. Points represent relative gene expression calculated from CT values from triplicate measurements of an individual sputum sample. Transcriptional activity is shown relative to the endogenous housekeeping gene oprI. (B) Expression of diverse iron uptake pathways within CF sputum. feoA and feoB encode proteins that transport Fe(II), while fptA, pvdA, and hasAp encode proteins that are involved in Fe(III) acquisition. Expression levels are shown compared to those in laboratory cultures treated with Fe(II), Fe(III), and no iron as described above.
FIG 3 (A) Fe(II)-relevant gene expression in CF sputum. bqsS is upregulated in planktonic cultures of P. aeruginosa in response to 50 µM Fe(II) (black) relative to 50 µM Fe(III) (white) or no treatment (light gray). A similar result is seen with bqsR. Points represent average CT values from three independent experiments; bars represent the standard deviations. By comparison, expression levels of these Fe(II)-sensitive genes in CF sputum (dark gray) vary over 5 orders of magnitude. Points represent relative gene expression calculated from CT values from triplicate measurements of an individual sputum sample. Transcriptional activity is shown relative to the endogenous housekeeping gene oprI. (B) Expression of diverse iron uptake pathways within CF sputum. feoA and feoB encode proteins that transport Fe(II), while fptA, pvdA, and hasAp encode proteins that are involved in Fe(III) acquisition. Expression levels are shown compared to those in laboratory cultures treated with Fe(II), Fe(III), and no iron as described above.CC BY-NC-SA · PubMed Central
FIG 4 (A and B) Biofilm growth prevention under aerobic conditions [~98% Fe(III)] (A) and anaerobic conditions [~10 µM Fe(II) and 10 µM Fe(III)] (B) by conalbumin [a Fe(III) chelator] and ferrozine [a Fe(II) chelator]. (C and D) Biofilm dissolution under aerobic (C) and anaerobic (D) conditions by conalbumin and ferrozine. In all cases, chelator effects are mitigated by the addition of Fe in excess of the chelation capacity [80 µM Fe(III) under oxic conditions; Fe(II) under anoxia]. Asterisks represent significance versus untreated controls. Error bars represent standard errors of the means (n = 12).
FIG 4 (A and B) Biofilm growth prevention under aerobic conditions [~98% Fe(III)] (A) and anaerobic conditions [~10 µM Fe(II) and 10 µM Fe(III)] (B) by conalbumin [a Fe(III) chelator] and ferrozine [a Fe(II) chelator]. (C and D) Biofilm dissolution under aerobic (C) and anaerobic (D) conditions by conalbumin and ferrozine. In all cases, chelator effects are mitigated by the addition of Fe in excess of the chelation capacity [80 µM Fe(III) under oxic conditions; Fe(II) under anoxia]. Asterisks represent significance versus untreated controls. Error bars represent standard errors of the means (n = 12).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 185

Metadata

Authors
Hunter, R. C., Asfour, F., Dingemans, J., Osuna, B. L., Samad, T., Malfroot, A., Cornelis, P., & Newman, D. K.
Affiliations
  • California Institute of Technology (US)
  • Children's Hospital Los Angeles (US)
  • Vrije Universiteit Brussel (BE)
  • University of Southern California (US)
  • Universitair Ziekenhuis Brussel (BE)
  • Department of Bioengineering Sciences, Research Group Microbiology, Flanders Interuniversity Institute of Biotechnology (VIB), Vrije Universiteit Brussel, Brussels, Belgium
Venue
mBio
Published
2013-08-30
Volume
4
Issue
4
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2100199965
Cited by
173
References
53
Citations by year
2026: 8 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 11 · 2019: 22 · 2018: 16 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 14 · 2013: 3
FWCI
7.61
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • SCK CEN Institutional Repository (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • California Institute of Technology
  • Agentschap voor Innovatie door Wetenschap en Technologie
  • National Institutes of Health (1k99hl114862-01)
  • National Heart, Lung, and Blood Institute (R00HL114862, 1K99HL114862, R01HL117328, K99 HL114862)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords
cystic fibrosis, Pseudomonas aeruginosa, ferrous iron, iron(III), iron bioavailability, iron oxidation state, biofilm formation, iron chelation therapy, anoxia, chronic lung infection, disease severity
MeSH terms
Bacterial Proteins, Cystic Fibrosis, Ferrous Compounds, Humans, Iron, Lung, Pseudomonas aeruginosa, Biofilms, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.